Schedules of Controlled Substances: Rescheduling of Suvorexant, Lemborexant, and Daridorexant from Schedule IV into Schedule V
DEA proposes rescheduling suvorexant, lemborexant, and daridorexant from Schedule IV to Schedule V, reducing regulatory burden for dispensers.
Aforeworn detected this change in the Pharmacy & Controlled Substances space on August 10, 2026 and published this briefing so affected operators are forewarned rather than caught off guard. It is rated Medium urgency. Independent pharmacies, retail chains, compounding pharmacies, and long-term-care pharmacies that dispense these medications. should confirm how it applies to their specific situation before acting. There is a time constraint attached: Not specified in the excerpt; check the Federal Register notice for comment period and effective date.. Acting after that point can mean penalties, a lapsed licence, or lost eligibility — exactly the kind of surprise Aforeworn exists to prevent. Aforeworn monitors Pharmacy & Controlled Substances continuously and turns every detected change into a plain-English briefing like this one, so you always know first. Forewarned is forearmed.
What changed
These three insomnia drugs would move from Schedule IV to Schedule V, easing prescribing and dispensing requirements (e.g., lower record-keeping and refill restrictions).
Who it affects
Independent pharmacies, retail chains, compounding pharmacies, and long-term-care pharmacies that dispense these medications.
What you must do
Monitor the final rule and update internal procedures, training, and PDMP workflows to align with Schedule V requirements once effective.
Deadline
Not specified in the excerpt; check the Federal Register notice for comment period and effective date.
Never miss a change like this again
Aforeworn watches Pharmacy & Controlled Substances around the clock and alerts you the moment a rule moves — with a plain-English brief on what to do.
Start your free trialRelated changes in Pharmacy & Controlled Substances
- Congress Introduces SAFE Drugs Act of 2025, Expanding FDA Oversight of Compounded GLP-1 Drugs and Telehealth Providers - dykema.com
- Court Rules Feds Need Warrant to Access Drug Prescriptions Database - American Civil Liberties Union
- Wisconsin bill would crack down on predatory practices by pharmacy benefit managers - wpr.org
- Utah eyes applications for new independent medical cannabis pharmacy in ‘underserved’ area - utahnewsdispatch.com
- Pa. legislators passed a law to regulate pharmacy middlemen. But the state doesn't enforce it. - penncapital-star.com